We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Ribosome Malfunction May Cause Cancer

By Biotechdaily staff writers
Posted on 24 Jan 2003
A study has found that the rare genetic syndrome dyskeratosis congenita (DC) is caused by ribosome malfunction and not by telomere shortening as had been previously thought. More...
The study appeared in the January 10, 2003, issue of Science.

Dyskeratosis congenita is an extremely rare, fatal X-linked recessive disease that results in premature aging, severe anemia due to bone marrow failure, dyskeratosis of the nails, skin hyperpigmentation, and cancer. It is caused by mutations in the DKC1 gene that encodes the protein dyskerin.

In order to study DC, investigators from the Memorial Sloan-Kettering Cancer Center (New York, NY, USA; www.mskcc.org) genetically engineered a line of DKC1 mutant mice that accurately expressed the phenotypes found in DC. All the major features of DC, including premature aging, dyskeratosis of the skin, bone marrow failure, and susceptibility to tumor development, showed up in the first and second-generation mice. However, overt defects in telomere length were only evident beginning with the fourth or fifth generations. This showed that the primary cause of DC was not telomerase impairment but rather deregulated ribosome function.

"This is the first example that shows that a defect in ribosome function may cause cancer,” explained first author Dr. Davide Ruggero, of the Molecular and Developmental Biology Laboratory at Memorial Sloan-Kettering. "In the past, we thought of ribosome as an important but passive ‘machine' in the synthesis of proteins while our study suggests that it plays a more active role in maintaining proper cellular function.”

The authors concluded that ribosome malfunction might be important in the genesis of cancer and might have clinical implications for the identification of new molecular targets for cancer drugs.



Related Links:
Memorial Sloan-Kettering Cancer Center

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Rheumatoid Factors (RF) Test
Rheumatoid Factors (RF)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.